

DECLARATION

I, Kathrine Elizabeth Theron, declare that this thesis is my own work. It is being submitted for the degree of Doctor of Philosophy in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

.....

.....day of....., 2010

Dedicated to:

My husband Nicky and my unborn son Pieter,
for giving me the strength to persevere and the
courage to face each new day.

My family, for always believing in me.

PUBLICATIONS AND PRESENTATIONS ARISING FROM THIS STUDY

Publications:

Scholtz K. E., Penny C. B. and Hosie M. J. (2008) A High Resolution SEM Study on the Effects of RU486, Used as a Postcoital Contraceptive, on the Rat Uterus During Early Pregnancy. *Cell Biology International*, 32, 436-446.

Conference presentations:

Health Science Faculty Research Day, University of the Witwatersrand, RSA (20th August 2008)
– Oral presentation in the subgroup Molecular and Comparative Biosciences.

A High Resolution SEM Study on the Effects of RU486, Used as a Postcoital Contraceptive, on the Rat Uterus during Early Pregnancy.

Molecular and Cell Biology Group (MCBG) of South Africa Symposium, University of Pretoria, South Africa (17th October 2007) – poster presentation.

A High Resolution SEM Study on the Effects of RU486, Used as a Postcoital Contraceptive, on the Rat Uterus during Early Pregnancy.

46th Annual Meeting of the American Society of Cell Biology (ASCB), San Diego, USA (9-14th December 2006) – Poster presentation

An SEM Study on the Effects of RU486, Used as a Postcoital Contraceptive, on the Rat Uterus during Early Pregnancy.

ABSTRACT

Tissue specific regulation of the progesterone receptor is central to female health. The synthetic steroid, RU486 is a partial progesterone and oestrogen receptor antagonist, functioning to actively silence progesterone receptor gene associated transcription. For this reason, it has been used both as a contraceptive and quite controversially as an abortive agent.

In this study, both cellular and gene specific effects of RU486 were investigated in a rat model of early pregnancy, this including the key phases of the plasma membrane transformation, the window of receptivity and early implantation. As all of these stages are hormonally regulated by progesterone and oestrogen, the focus here was to elucidate the mechanisms of action of a single dose of RU486, used as a postcoital contraceptive, at day 3.0 of pregnancy, to successfully prevent implantation of a viable blastocyst and subsequent pregnancy.

In association with the cellular preparation of uterine epithelial cells for implantation, selected molecular targets and events were investigated at a protein and gene expression level, both prior to and after RU486 treatment, to assess the effects of either a deficit or excessive expression of these gene products on uterine preparation and eventual implantation. Factors here included the progesterone receptor, markers of apoptosis (Bax and Bcl2), mediators of angiogenesis (VEGF, bFGF and PDGF) and biomarkers of endometrial implantation (LIF, Calcitonin and Muc-1).

Together, an ultrastructural and light microscopy analysis showed RU486 to morphologically alter the uterine endometrial cells and to disrupt the plasma membrane transformation of early pregnancy, predisposing these cells towards apoptosis. In association with this, progesterone receptor gene and protein expression was ubiquitously decreased throughout pregnancy.

With regards to the implantation process of early pregnancy, the luminal epithelial cells undergo apoptosis to allow the hatching blastocyst to penetrate and implant within the uterine wall. This is partially mediated by the ratio of the expression of the apoptotic factors Bax and Bcl-2. Surprisingly here, RU486 caused an overall anti-apoptotic environment, despite previously observed high levels of apoptotic activity. This indicates that factors other than Bax and Bcl-2 influence the RU486-induced apoptosis.

A crucial event of early pregnancy is the establishment of an adequate blood supply to sustain and nourish the implanting blastocyst. There was a decided reduction in the angiogenic response of early pregnancy, as a direct consequence of RU486 treatment; the normally high levels of VEGF and bFGF during early pregnancy, were markedly decreased at all three days of pregnancy. This was reflected in the lack of increased vascularisation as normally signalled by the indicator dye, Pontamine Sky blue. In contrast to the overall increase in VEGF and bFGF at the time of blastocyst implantation during early pregnancy, increased PDGF expression was localised to the implantation sites, strongly suggesting a role for this angiogenic factor in endothelial cell proliferation.

The endometrial biomarkers are indicative of implantation, their expression patterns varying around the phase of implantation. These markers are essential to implantation, as when LIF and Calcitonin are deregulated and Muc-1 persists on the apical surface of the endometrium, implantation fails.

These events are precisely what occur following RU486 treatment.

In summary, the overall effects of RU486 in the rat model of early pregnancy, when used as a postcoital contraceptive, indicate highly effective inhibition of progesterone and oestrogen effects on the endometrium, mediated by their receptors. More specifically, the structural and molecular events mirror those described in ovariectomised animal models, suggesting a hormonally under-stimulated endometrium. Clearly from the present study, the precise priming of the endometrium in preparation for blastocyst implantation is severely impaired by RU486 through a number of signalling pathways, thus predisposing the uterus to pregnancy failure.

ACKNOWLEDGEMENTS

I wish to thank my supervisors, Associate Professor Margot Hosie and Doctor Clement Penny for their invaluable support, guidance and assistance throughout my PhD.

I wish to thank the Head of the School of Anatomical Sciences. I value my time spent in the school and all the knowledge and lessons I take with me.

The financial assistance of the National Research Foundation (NRF) towards this research is hereby acknowledged. Opinions expressed and conclusions arrived at, are those of the author and are not necessarily to be attributed to the NRF.

To the University of the Witwatersrand Financial Aid and Scholarships for financial assistance during the course of this degree.

To all the technical staff in the School of Anatomical Sciences for all their hard work and patience in assisting me with my techniques.

I wish to thank CSIR, Pretoria, South Africa for the use of their scanning electron microscopy and Mrs Loukie Adlem for her guidance in the use of the microscope.

I wish to thank the EM unit at Medunsa University, South Africa for the use of their transmission electron microscope and Dr Chantelle Baker for her assistance and guidance in the use of the microscope.

I would also like to thank my friend and colleague Dr Victoria Gibbon for the years of friendship, coffee breaks, sound advice and assistance with the RT-qPCR analysis.

To all my friends who have given me love, support and encouragement throughout the years, thank you. To Natalie, Louis and Tacara, thank you for putting up with me in the last few weeks and for giving me the strength and encouragement to see it through to the end.

Finally, my grateful thanks to my family; my Dad, Mom and Stepmom for giving me constant encouragement and support, and to my sister for her love, and faith in me and my abilities throughout the years. And most importantly I'd like to thank my loving and ever patient husband, Nicky. Thank you for always believing in me and for being proud of me no matter what. I owe you big time baby!!

TABLE OF CONTENTS

DECLARATION.....	i
DEDICATION.....	ii
PUBLICATIONS AND PRESENTATIONS.....	iii
ABSTRACT.....	iv
ACKNOWLEDGEMENTS.....	vi
TABLE OF CONTENTS.....	vii
LIST OF FIGURES.....	xvii
LIST OF GRAPHS.....	xxii
LIST OF TABLES.....	xxvi
NOMENCLATURE.....	xxxi
CHAPTER 1: GENERAL INTRODUCTION.....	1
1.1 Emergency Contraception.....	1
1.2 The Progesterone Receptor Modulator, RU486.....	2
1.2.1 Mode of action of RU486.....	3
1.2.1.1 Overview of the Progesterone Receptor (PR).....	3
1.2.1.2 RU486 and the PR.....	4
1.2.1.3 RU486 Effects on the Endometrium.....	7
1.3 Early Pregnancy.....	7
1.3.1 Blastocyst implantation.....	7
1.3.2 The window of receptivity.....	8
1.3.3 Ovarian hormonal control.....	8
1.4 RU486 and Early Pregnancy.....	9
CHAPTER 2: MATERIALS AND METHODS.....	11
2.1 Animals.....	11
2.2 Treatment Regime.....	11
2.3 Characterisation of Surface Ultrastructural Changes in the RU486-Treated Rat Uterus.....	12
2.3.1 Scanning electron microscopy.....	12
2.3.1.1 Tissue Preparation.....	12
2.3.1.2 Data Collection.....	13
2.3.1.3 Morphological Analysis of Tissue.....	13
2.3.2 Transmission electron microscopy.....	13
2.3.2.1 Tissue Preparation.....	13
2.3.2.2 Data Collection.....	14
2.3.2.3 Morphological Analysis of Tissue.....	14

2.4	Characterisation of the Progesterone Receptor, Endometrial Biomarker, Angiogenic Pathway-Related and Apoptotic Pathway-Related Gene mRNA Expression in the RU486-Treated Rat Uterus.....	15
2.4.1	RNA extraction.....	15
2.4.1.1	Total RNA Cleanup.....	17
2.4.1.2	RNA Integrity and Concentration.....	17
2.4.2	Primer design and synthesis.....	19
2.4.3	Complimentary DNA (cDNA) synthesis.....	20
2.4.4	Real-time quantitative reverse transcription polymerase chain reaction (real-time RT-qPCR).....	22
2.4.4.1	TaqMan Gene Expression Assays.....	22
2.4.4.1.1	TaqMan gene expression assay real-time RT-qPCR optimisation.....	24
2.4.4.1.2	TaqMan gene expression assay real-time RT-qPCR.....	24
2.4.4.2	SYBR Green RT-qPCR Optimisation.....	25
2.4.4.2.1	PCR product gel electrophoresis.....	26
2.4.4.2.2	SYBR green RT-qPCR analysis.....	26
2.4.4.3	Data Collection.....	27
2.5	Immunofluorescence (IF).....	28
2.5.1	Tissue preparation for IF.....	28
2.5.1.1	IF Section Preparation.....	28
2.5.2	Negative controls.....	30
2.5.3	Data collection.....	30
2.5.4	Statistical analysis.....	31
CHAPTER 3: THE EFFECTS OF RU486 ON THE WINDOW OF RECEPTIVITY		
3.1	INTRODUCTION.....	32
3.1.1	Increased Vascular Permeability.....	32
3.1.2	The Plasma Membrane Transformation of Early Pregnancy.....	32
3.1.3	Apical Surface Changes.....	33
3.1.4	Cellular Changes.....	34
3.1.5	The Basal Plasma Membrane Transformation.....	34
3.1.6	Decidualisation.....	35
3.2	RESULTS.....	37
3.2.1	Characterisation of Surface Ultrastructural Changes in the RU486-Treated Rat Uterus.....	37
3.2.1.1	Folding of the uterine surface.....	37
3.2.1.2	Luminal secretions.....	45
3.2.1.3	Large cell surface protrusions.....	45
3.2.1.4	Luminal epithelial cells.....	47

3.2.1.5	Microvilli concentration and appearance.....	49
3.2.1.6	Cell borders of the uterine epithelial cells.....	49
3.2.1.7	Cell apices of the uterine epithelial cells.....	51
3.2.1.8	Uterine epithelial cell lipids.....	53
3.2.1.9	The Basal plasma membrane of uterine epithelial cells.....	53
3.2.1.10	Decidual cells.....	53
3.2.1.11	Morphology of the glands.....	55
3.2.1.12	Apoptotic bodies.....	55
3.3	DISCUSSION.....	59
3.3.1	The Effects of RU486 on Vascular Permeability.....	59
3.3.2	The Effects of RU486 on Uterine Folding.....	60
3.3.3	The Effects of RU486 on the Plasma Membrane Transformation of Early Pregnancy.....	61
3.3.4	The Effects of RU486 on the Luminal Epithelial Cells.....	62
3.3.5	The Effects of RU486 on the Lipid Droplets.....	63
3.3.6	The Effects of RU486 on the Basal Plasma Membrane.....	63
3.3.7	The Effects of RU486 on the Large Cell Surface Protrusions.....	64
3.3.8	The Effects of RU486 on Glandular Morphology.....	64
3.3.9	The RU486-Induced Increase in Apoptotic Activity within the Endometrium during Early Pregnancy.....	65
3.3.10	The Effects of RU486 on Decidualisation.....	65
CHAPTER 4: THE EFFECTS OF RU486 ON PROGESTERONE RECEPTOR LOCALISATION AND EXPRESSION IN THE RAT UTERUS DURING EARLY PREGNANCY		
4.1	INTRODUCTION.....	67
4.1.1	The Structure and Function of the Progesterone Receptor (PR).....	67
4.1.1.1	The PR isoforms.....	67
4.1.1.2	PR activation.....	68
4.1.1.3	The role of PR during early pregnancy.....	69
4.1.1.3.1	Ovarian Hormonal Regulation of PR in the Endometrium.....	70
4.1.1.3.2	Function of the PR Isoforms in the Endometrium.....	70
4.2	RESULTS.....	72
4.2.1	Immunofluorescence Analysis of PR Protein Spatiotemporal Expression Pattern in the RU486-Treated Rat Endometrium.....	72
4.2.1.1	The Spatiotemporal expression pattern of PR protein expression in the control pregnant animals.....	72
4.2.1.2	The effects of RU486 on the spatiotemporal expression pattern of the PR protein during early pregnancy.....	76
4.2.2	The Effects of RU486 on PR Gene Expression in the Rat Uterus during Early Pregnancy.....	82

4.2.2.1	Relative quantification (RQ) analysis of PR gene expression in the control pregnant animals.....	82
4.2.2.2	Relative quantification (RQ) analysis of the effects of RU486 on PR gene expression.....	82
4.3	DISCUSSION.....	84
4.3.1	The Effects of RU486 on Progesterone Receptor Expression and Localisation within the Rat Endometrium.....	84
CHAPTER 5: ROLE OF RU486 IN INDUCING APOPTOSIS DURING EARLY PREGNANCY; ASSESSMENT USING THE BAX/BCL-2 INDEX		
5.1	INTRODUCTION.....	90
5.1.1	Cell Death.....	90
5.1.2	Progesterone Regulation of Apoptosis in the Endometrium.....	92
5.1.3	Apoptosis Pathways.....	94
5.1.3.1	The tumour necrosis factor receptor (TNFR) gene superfamily.....	94
5.1.3.2	The Bcl-2 family.....	95
5.1.3.2.1	Bax and Bcl-2.....	95
5.2	RESULTS.....	98
5.2.1	Immunofluorescence Analysis of Bax and Bcl-2 Protein Expression in the RU486-Treated Rat Endometrium.....	98
5.2.1.1	The spatiotemporal pattern of Bax and Bcl-2 proteins expression and analysis of the Bax/Bcl-2 index in the control pregnant animals.....	104
5.2.1.2	The effects of RU486 on the spatiotemporal expression pattern of the Bax and Bcl-2 proteins, and the Bax/Bcl-2 index during early pregnancy.....	109
5.2.2	The Effects of RU486 on Apoptotic Pathway-Related Gene Expression in the Rat Uterus during Early Pregnancy.....	118
5.2.2.1	Relative quantification (RQ) analysis of Bax and Bcl-2 gene expression in the control pregnant animals.....	118
5.2.2.2	Relative quantification (RQ) analysis of the effects of RU486 on Bax and Bcl-2 gene expression.....	118
5.3	DISCUSSION.....	121
5.3.1	Alterations in the Bax/Bcl-2 Ratio is Not Responsible for the Increase in RU486-Induced Apoptosis.....	121
CHAPTER 6: THE EFFECTS OF RU486 ON ANGIOGENESIS DURING EARLY PREGNANCY IN THE RAT UTERUS		
6.1	INTRODUCTION.....	127
6.1.1	Angiogenesis and the Endometrium.....	127
6.1.1.1	Vascular endothelial growth factor (VEGF).....	132
6.1.1.2	Basic fibroblast growth factor (bFGF).....	134
6.1.1.3	Platelet-derived growth factor (PDGF).....	136
6.2	RESULTS.....	139

6.2.1	Immunofluorescence Analysis of VEGF, bFGF and PDGF Protein Spatiotemporal Expression Patterns in the RU486-Treated Rat Endometrium.....	139
6.2.1.1	The spatiotemporal expression pattern of the VEGF and bFGF proteins within the control pregnant animals.....	139
6.2.1.2	The effects of RU486 on VEGF and bFGF protein spatiotemporal expression patterns.....	149
6.2.1.3	The spatiotemporal expression pattern of the PDGF protein within the control pregnant animals.....	163
6.2.1.4	The effects of RU486 on the spatiotemporal expression pattern of the PDGF protein	169
6.2.2	The Effects of RU486 on Angiogenic Pathway-Related Gene Expression in the Rat Uterus during Early Pregnancy.....	176
6.2.2.1	Relative quantification (RQ) analysis of VEGF and bFGF gene expression.....	176
6.2.2.1.1	Analysis of VEGF and bFGF Gene Expression in the Control Pregnant Animals.....	176
6.2.2.1.2	Analysis of the Effects of RU486 on VEGF and bFGF Gene Expression.....	179
6.2.2.2	Relative quantification (RQ) analysis of PDGF gene expression.....	179
6.2.2.2.1	Analysis of PDGF Gene Expression in the Control Pregnant Animals.....	179
6.2.2.2.2	Analysis of the Effects of RU486 on PDGF Gene Expression.....	179
6.3	DISCUSSION.....	182
6.3.1	The Effects of RU486 on the Angiogenic Pathway-Related Growth Factors....	182
6.3.1.1	Vascular permeability.....	182
6.3.1.2	Endometrial cell proliferation and differentiation.....	182
6.3.1.2.1	The Spatiotemporal Expression Pattern of VEGF and bFGF in the Pregnant Rat Endometrium.....	182
6.3.1.2.1.1	Regulation of VEGF and bFGF.....	186
6.3.1.2.1.2	The effects of RU486 on VEGF and bFGF expression patterns.....	187
6.3.1.2.2	The Spatiotemporal Expression Pattern of PDGF in the Pregnant Rat Endometrium.....	191
6.3.1.2.2.1	The effects of RU486 on PDGF expression patterns.....	193
6.3.1.3	Endothelial cell proliferation.....	195
6.3.1.4	The angiogenic pathway-related growth factors and the decidual response.....	197
CHAPTER 7: THE EFFECTS OF RU486 ON SELECTED ENDOMETRIAL BIOMARKERS DURING EARLY PREGNANCY IN THE RAT UTERUS		
7.1	INTRODUCTION.....	200

7.1.1	Endometrial Biomarkers.....	200
7.1.1.1	Leukaemia inhibitory factor (LIF).....	201
7.1.1.2	Mucin 1 (Muc-1).....	204
7.1.1.3	Calcitonin.....	206
7.2	RESULTS.....	209
7.2.1	Immunofluorescence Analysis of the Spatiotemporal Expression Patterns of the LIF, Muc-1 and Calcitonin Proteins in the RU486-Treated Rat Endometrium.....	209
7.2.1.1	The spatiotemporal expression pattern of the LIF, Muc-1 and Calcitonin proteins within the control pregnant animals.....	209
7.2.1.2	The effects of RU486 on the spatiotemporal protein expression patterns of LIF, Muc-1 and Calcitonin	217
7.2.2	The Effects of RU486 on Gene Expression of the Endometrial Biomarkers in the Rat Uterus during early Pregnancy	234
7.2.2.1	Relative quantification (RQ) analysis of LIF, Muc-1 and Calcitonin gene expression in the control pregnant animals.....	234
7.2.2.2	Relative quantification (RQ) analysis of the effects of RU486 on LIF, Muc-1 and Calcitonin gene expression.....	237
7.3	DISCUSSION.....	239
7.3.1	The Effects of RU486 on Selected Endometrial Biomarkers of Receptivity during Early Pregnancy.....	239
7.3.1.1	The spatiotemporal expression pattern of LIF in the rat uterus during early pregnancy and the effects of RU486 on this expression.....	239
7.3.1.2	The spatiotemporal expression pattern of Muc-1 in the rat uterus during early pregnancy and the effects RU486 has on this expression.....	243
7.3.1.3	The spatiotemporal expression pattern of Calcitonin in the rat uterus during early pregnancy and the effects RU486 has on this expression.....	247
CHAPTER 8: GENERAL DISCUSSION		
8.1	The Use of RU486 as an Emergency Contraceptive.....	251
8.2	The Effects of RU486 on the Cellular Responses of Early Pregnancy.....	252
8.3	The Effects of RU486 on the Progesterone Receptor.....	252
8.4	Bax/Bcl-2 in Not the Pathway Regulating the RU486-Induced Increase in Apoptosis Observed in the Rat Endometrium.....	253
8.5	The Effects of RU486 on Selected Angiogenic Pathway-Related Growth Factor.....	253
8.6	The Effects of RU486 on Selected Endometrial Biomarkers of Receptivity during Early Pregnancy.....	255
8.7	The Hormonally Under-stimulated Endometrium of RU486-Treated Animals.....	256
REFERENCE LIST.....		257

E-REFERENCES.....	279
APPENDIX	
A. SOLUTION AND RECIPES	
9.1	Vaginal Smears.....280
9.1.1	Shorr's stain.....280
9.1.2	Method of staining.....280
9.2	Treatment Regime.....280
9.2.1	Vehicle.....280
9.2.2	Mifepristone in peanut oil.....280
9.3	Sacrificing of Animals.....281
9.3.1	Rompin-ketamin.....281
9.3.2	1 % Pontamine sky blue.....281
9.3.3	1% Saline.....281
9.4	Scanning Electron Microscopy.....281
9.4.1	Phosphate buffer (pH 7.2).....281
9.4.2	2.5% Gluteraldehyde.....281
9.4.3	1% Osmium tetroxide.....281
9.5	Transmission Electron Microscopy.....282
9.5.1	2.5% Gluteraldehyde.....282
9.5.2	1% Osmium tetroxide.....282
9.5.3	Spurr's resin.....282
9.5.4	Toluidine blue & pyronin Y solution.....282
9.5.5	5% Aqueous uranyl acetate.....282
9.5.6	Reynold's modified lead citrate.....282
9.6	Real-Time RT-qPCR.....283
9.6.1	β -mercaptoethanol in RLT buffer.....283
9.6.2	RPE buffer in ethanol.....283
9.6.3	0.1% Diethyl pyrocarbonate (DEPC) water.....283
9.6.4	10X Tris (0.89M)-boric acid (0.02M) EDTA (0.89M) (TBE) buffer.....283
9.6.5	1X TBE buffer.....283
9.6.6	1% Agarose gel in 1XTBE buffer.....283
9.6.7	1.5% Agarose gel in 1XTBE buffer.....283
9.7	Immunofluorescence.....284
9.7.1	10% Buffered formalin.....284
9.7.2	2% 3-Aminopropyl-triethoxysilane in acetone treated slides.....284
9.7.3	Phosphate buffered saline (PBS) pH 7.6.....284

9.7.4	0.1% PBS/Bovine serum albumin (BSA).....	284
9.7.5	0.1% Triton-X100 in 0.1%BSA/PBS.....	284
9.7.6	Tris-ethylenediamine tetraacetic acid (EDTA) buffer (pH 9.0).....	285
9.7.7	Polyclonal goat anti-LIF in 0.1%BSA/PBS (1:75).....	285
9.7.8	Polyclonal goat anti-Muc-1 in 0.1%BSA/PBS (1:100).....	285
9.7.9	Polyclonal rabbit anti-Calcitonin in 0.1%BSA/PBS (1:100).....	285
9.7.10	Donkey anti-goat IgG conjugated to alexa flour 488 in 0.1%BSA/PBS (1:100).....	285
9.7.11	Donkey anti-goat IgG conjugated to alexa flour 488 in 0.1%BSA/PBS (1:150).....	285
9.7.12	Goat anti-rabbit IgG conjugated to alexa flour 594 in 0.1%BSA/PBS 1:150).....	285
9.7.13	Dapi in 0.1%BSA/PBS (1:500).....	286
9.7.14	Sodium citrate buffer (10mM sodium citrate, 0.05% Tween 20, pH 6.0).....	286
9.7.15	Polyclonal goat anti-VEGF in 0.1%BSA/PBS (1:50).....	286
9.7.16	Polyclonal rabbit anti-bFGF in 0.1%BSA/PBS (1:50).....	286
9.7.17	Polyclonal rabbit anti-PDGF in 0.1%BSA/PBS (1:75).....	286
9.7.18	Donkey anti-goat IgG conjugated to alexa flour 488 in 0.1%BSA/PBS (1:200).....	286
9.7.19	Donkey anti-rabbit IgG conjugated to alexa flour 594 in 0.1%BSA/PBS (1:200).....	286
9.7.20	Polyclonal rabbit anti-Bax in 0.1%BSA/PBS (1:50).....	287
9.7.21	Monoclonal mouse anti-Bcl-2 in 0.1%BSA/PBS (1:75).....	287
9.7.22	Polyclonal rabbit anti-PR in 0.1%BSA/PBS (1:50).....	287
9.7.23	Donkey anti-goat IgG conjugated to alexa flour 488 in 0.1%BSA/PBS (1:200).....	287
9.7.24	Donkey anti-rabbit IgG conjugated to alexa flour 594 in 0.1%BSA/PBS (1:200).....	287
9.7.25	Donkey anti-mouse IgG conjugated to alexa flour 594 in 0.1%BSA/PBS (1:200).....	287

B. mRNA SEQUENCES DEMONSTRATING THE PRIMER BINDING SITES FOR EACH PRIMER PAIR

9.8	PR mRNA Sequence (3064ps).....	288
9.9	B-action mRNA Sequence (1275bps).....	289
9.10	VEGF mRNA Sequence (703bps).....	289
9.11	bFGF mRNA Sequence (1269bps).....	290
9.12	PDGF mRNA Sequence (543bps).....	290
9.13	Bax mRNA Sequence (742bps).....	290

9.14	Bcl-2 mRNA Sequence (1179bps).....	291
C. STATISTICAL ANALYSIS FOR IMMUNOFLUORESCENCE		
9.15	Statistical Analysis of Protein Expression of the Progesterone Receptor (PR).....	292
9.15.1	Statistical analysis of PR protein expression.....	292
9.15.1.1	Summaries of Statistics Tests for Significant Differences in the Mean PR Protein Expression in the Regions of Interest of the Control Pregnant and RU486-Treated Animals at Days 4.5, 5.5 and 6.5 of Pregnancy.....	292
9.16	Statistical Analysis of Protein Expression of the Apoptosis Pathway-Related Factors.....	294
9.16.1	Statistical analysis of Bax protein expression.....	294
9.16.1.2	Summaries of Statistics Tests for Significant Differences in the Mean Bax Protein Expression in the Regions of Interest of the Control Pregnant and RU486-Treated Animals at Days 4.5, 5.5 and 6.5 of Pregnancy.....	294
9.16.2	Statistical analysis of Bcl-2 protein expression.....	297
9.16.2.1	Summaries of Statistics Tests for Significant Differences in the Mean Bcl-2 Protein Expression in the Regions of Interest of the Control Pregnant and RU486-Treated Animals at Days 4.5, 5.5 and 6.5 of Pregnancy.....	297
9.17	Statistical Analysis of Protein Expression of the Angiogenic Pathway-Related Growth Factors.....	300
9.17.1	Statistical analysis of VEGF protein expression.....	300
9.17.1.1	Summaries of Statistics Tests for Significant Differences in the Mean VEGF Protein Expression in the Regions of Interest of the Control Pregnant and RU486-Treated Animals at Days 4.5, 5.5 and 6.5 of Pregnancy.....	300
9.17.2	Statistical analysis of bFGF protein expression.....	304
9.17.2.1	Summaries of Statistics Tests for Significant Differences in the Mean bFGF Protein Expression in the Regions of Interest of the Control Pregnant and RU486-Treated Animals at Days 4.5, 5.5 and 6.5 of Pregnancy.....	304
9.17.3	Statistical analysis of PDGF protein expression.....	308
9.17.3.1	Summaries of Statistics Tests for Significant Differences in the Mean PDGF Protein Expression in the Regions of Interest of the Control Pregnant and RU486-Treated Animals at Days 4.5, 5.5 and 6.5 of Pregnancy.....	308
9.18	Statistical Analysis of Protein Expression of the Endometrial Biomarkers	312
9.18.1	Statistical analysis of LIF protein expression.....	312
9.18.1.1	Summaries of Statistics Tests for Significant Differences in the Mean LIF Protein Expression in the Regions of Interest of the Control Pregnant and RU486-Treated Animals at Days 4.5, 5.5 and 6.5 of Pregnancy.....	312

9.18.2 Statistical analysis of Muc-1 protein expression.....	314
9.18.1.2 Summaries of Statistics Tests for Significant Differences in the Mean Muc-1 Protein Expression in the Regions of Interest of the Control Pregnant and RU486-Treated Animals at Days 4.5, 5.5 and 6.5 of Pregnancy.....	314
9.18.3 Statistical analysis of Calcitonin protein expression.....	317
9.18.1.2 Summaries of Statistics Tests for Significant Differences in the Mean Calcitonin Protein Expression in the Regions of Interest of the Control Pregnant and RU486-Treated Animals at Days 4.5, 5.5 and 6.5 of Pregnancy.....	317

LIST OF FIGURES

Figure	Page
CHAPTER 1: GENERAL INTRODUCTION	
Figure 1.1 Geometric isomers of the steroid hormone progesterone and the antagonist RU486.	2
Figure 1.2 The four functional domains of the progesterone receptor.	3
Figure 1.3 Activation of the progesterone receptor by progesterone.	4
Figure 1.4 Progesterone receptor (PR) activation by progesterone receptor ligands.	6
CHAPTER 2: MATERIALS AND METHODS	
Figure 2.1 A 1% Agarose gel showing RNA samples extracted using the Qiagen RNeasy Mini Kit.	19
Figure 2.2 The 5' nuclease assay process that takes place during TaqMan real-time PCR.	23
CHAPTER 3: THE EFFECT OF RU486 ON THE WINDOW OF RECEPTIVITY	
Figure 3.1 Morphology of the uterine surface of the pregnant rat uterus.	38
Figure 3.2 Ultrastructure of the small secretory droplets.	38
Figure 3.3 Electron micrographs of the large cell surface protrusions of the pregnant animals treated with RU486 at day 3.0 of pregnancy.	40
Figure 3.4 Toluidine Blue semi-thin sections of the control pregnant animals.	42
Figure 3.5 Toluidine Blue semi-thin sections of the RU486-treated animals.	44
Figure 3.6 Low and high power micrographs of the control pregnant rat uterus.	46
Figure 3.6 cont. Low and high power micrographs of the control pregnant rat uterus.	48
Figure 3.7 Low and high power micrographs of the RU486-treated pregnant rat uterus.	50
Figure 3.7 cont. Low and high power micrographs of the RU486-treated pregnant rat uterus.	52
Figure 3.8 Scanning electron micrographs of the uterine epithelial cells at days 4.5, 5.5 and 6.5 of pregnancy in the rat uterus.	54
Figure 3.9 Scanning electron micrographs of the uterine epithelial cells at days 4.5, 5.5 and 6.5 of pregnancy, following treatment with RU486 at day 3 of pregnancy.	56
Figure 3.10 Toluidine Blue light microscopy images of the glandular epithelium in the control pregnant and RU486-treated endometrium.	57
Figure 3.11 Light and transmission electron micrographs depicting the RU486-induced increase in apoptotic activity.	58
CHAPTER 4: THE EFFECT OF RU486 ON PROGESTERONE RECEPTOR LOCALISATION AND EXPRESSION IN THE RAT UTERUS DURING EARLY PREGNANCY	
Figure 4.1 Schematic representation of the structural organisation of the two main PR isoforms, PR-A and PR-B.	68

Figure 4.2 Immunofluorescent images illustrating PR protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	75
Figure 4.3 Immunofluorescent images illustrating PR protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	77
Figure 4.4 Immunofluorescent images illustrating PR protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	79
Figure 4.5 Immunofluorescent images illustrating PR protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	81
 CHAPTER 5: ROLE OF RU486 IN INDUCING APOPTOSIS DURING EARLY PREGNANCY; ASSESSMENT USING THE BAX/BCL-2 INDEX	
Figure 5.1 Schematic representation of the differences observed between the two major forms of cell death: apoptosis (programmed cell death) and necrosis.	90
Figure 5.2 The characteristic cellular changes that occur during apoptosis.	91
Figure 5.3 Schematic representation of the different regions within the mouse and rat uterus.	93
Figure 5.4 Schematic representation of the apoptosis cascade and the function of Bax and Bcl-2 in this pathway.	95
Figure 5.5 Schematic representation of the Bax/Bcl-2 ratio which determines cell survival or cell death following the apoptotic stimulus.	96
Figure 5.6 Immunofluorescent images illustrating Bax protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	99
Figure 5.7 Immunofluorescent images illustrating Bax protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	101
Figure 5.8 Immunofluorescent images illustrating Bcl-2 protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	103
Figure 5.9 Immunofluorescent images illustrating Bcl-2 protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	105
Figure 5.10 Immunofluorescent images illustrating Bax protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	110
Figure 5.11 Immunofluorescent images illustrating Bax protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	112
Figure 5.12 Immunofluorescent images illustrating Bcl-2 protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	114
Figure 5.13 Immunofluorescent images illustrating Bcl-2 protein localisation in the	

glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	116
---	-----

CHAPTER 6: THE EFFECT OF RU486 ON ANGIOGENESIS DURING EARLY PREGNANCY IN THE RAT UTERUS

Figure 6.1 Schematic representation of the three different mechanisms of angiogenesis; sprouting, intussusception and elongation.	128
--	-----

Figure 6.2 Immunofluorescent images illustrating VEGF protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	144
--	-----

Figure 6.3 Immunofluorescent images illustrating VEGF protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	146
--	-----

Figure 6.4 Immunofluorescent images illustrating VEGF protein localisation in the blood vessels and the stroma surrounding the blood vessels of the implantation and non-implantation sites in the uteri of control pregnant rats.	148
---	-----

Figure 6.5 Immunofluorescent images illustrating bFGF protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	150
--	-----

Figure 6.6 Immunofluorescent images illustrating bFGF protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	152
--	-----

Figure 6.7 Immunofluorescent images illustrating bFGF protein localisation in the blood vessels and the stroma surrounding the blood vessels of the implantation and non-implantation sites in the uteri of control pregnant rats.	154
---	-----

Figure 6.8 Immunofluorescent images illustrating VEGF protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	156
--	-----

Figure 6.9 Immunofluorescent images illustrating VEGF protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	158
--	-----

Figure 6.10 Immunofluorescent images illustrating VEGF protein localisation in the blood vessels and the stroma surrounding the blood vessels of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	159
--	-----

Figure 6.11 Immunofluorescent images illustrating bFGF protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	160
---	-----

Figure 6.12 Immunofluorescent images illustrating bFGF protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	161
---	-----

Figure 6.13 Immunofluorescent images illustrating bFGF protein localisation in the blood vessels and the stroma surrounding the blood vessels of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	162
--	-----

Figure 6.14 Immunofluorescent images illustrating PDGF protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	166
---	-----

Figure 6.15 Immunofluorescent images illustrating PDGF protein localisation in the	
---	--

glandular epithelium and glandular stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	168
Figure 6.16 Immunofluorescent images illustrating PDGF protein localisation in the blood vessels and the stroma surrounding the blood vessels of the implantation and non-implantation sites in the uteri of control pregnant rats.	170
Figure 6.17 Immunofluorescent images illustrating PDGF protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	172
Figure 6.18 Immunofluorescent images illustrating PDGF protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	174
Figure 6.19 Immunofluorescent images illustrating PDGF protein localisation in the blood vessels and the stroma surrounding the blood vessels of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	175

CHAPTER 7: THE EFFECTS OF RU486 ON SELECTED ENDOMETRIAL BIOMARKERS DURING EARLY PREGNANCY IN THE RAT UTERUS

Figure 7.1 Schematic representation of the LIF receptor complex.	202
Figure 7.2 Schematic representation of the function of Muc-1 as an anti-adhesive molecule and a barrier to blastocyst implantation.	204
Figure 7.3 Immunofluorescent images illustrating LIF protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	216
Figure 7.4 Immunofluorescent images illustrating LIF protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	218
Figure 7.5 Immunofluorescent images illustrating Muc-1 protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	220
Figure 7.6 Immunofluorescent images illustrating Muc-1 protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	222
Figure 7.7 Immunofluorescent images illustrating Calcitonin protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	224
Figure 7.8 Immunofluorescent images illustrating Calcitonin protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of control pregnant rats.	226
Figure 7.9 Immunofluorescent images illustrating LIF protein localisation in the luminal epithelium and the subepithelial stroma of implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	228
Figure 7.10 Immunofluorescent images illustrating LIF protein localisation in the glandular stroma and the glandular stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	229
Figure 7.11 Immunofluorescent images illustrating Muc-1 protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	230

Figure 7.12 Immunofluorescent images illustrating Muc-1 protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	231
Figure 7.13 Immunofluorescent images illustrating Calcitonin protein localisation in the luminal epithelium and the subepithelial stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	232
Figure 7.14 Immunofluorescent images illustrating Calcitonin protein localisation in the glandular epithelium and the glandular stroma of the implantation and non-implantation sites in the uteri of RU486-treated pregnant rats.	233

APPENDIX B: mRNA SEQUENCES DEMONSTRATING THE PRIMER BINDING SITES FOR EACH PRIMER PAIR

Figure 9.1 PR mRNA sequence demonstrating the primer binding sites.	288
Figure 9.2 β -actin mRNA sequence demonstrating the primer binding sites.	289
Figure 9.3 VEGF mRNA sequence demonstrating the primer binding sites.	289
Figure 9.4 bFGF mRNA sequence demonstrating the primer binding sites.	290
Figure 9.5 PDGF mRNA sequence demonstrating the primer binding sites.	290
Figure 9.6 Bax mRNA sequence demonstrating the primer binding sites.	290
Figure 9.7 Bcl-2 mRNA sequence demonstrating the primer binding sites.	291

LIST OF GRAPHS

Graph	Page
CHAPTER 4: THE EFFECT OF RU486 ON PROGESTERONE RECEPTOR LOCALISATION AND EXPRESSION IN THE RAT UTERUS DURING EARLY PREGNANCY	
Graph 4.1 Graphical representation of the Mean $\pm$ SEM (Standard Error of the Mean) of PR protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	74
Graph 4.2 Graphical representation of the Mean $\pm$ SEM of PR protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular stroma (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	78
Graph 4.3 Graphical representation of the Mean $\pm$ SEM of PR protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	80
Graph 4.4 Graphical representation of PR gene expression as compared to day 5.5 in the control pregnant animals, the calibrator sample.	83
CHAPTER 5: ROLE OF RU486 IN INDUCING THR APOPTOSIS DURING EARLY PREGNANCY; ASSESSMENT USING THE BAX/BCL-2 INDEX	
Graph 5.1 Graphical representation of the Mean $\pm$ SEM of Bax protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	107
Graph 5.2 Graphical representation of the Mean $\pm$ SEM of Bcl-2 protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	107
Graph 5.3 Graphical representation of the Bax/Bcl-2 index values in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained by dividing the values of Bax protein fluorescent intensities by Bcl-2 protein fluorescent intensities.	108
Graph 5.4 Graphical representation of the Mean $\pm$ SEM of Bax protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	113
Graph 5.5 Graphical representation of the Mean $\pm$ SEM of Bcl-2 protein expression in the	

luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities. 113

Graph 5.6 Graphical representation of the Mean $\pm$ SEM of Bax protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities. 115

Graph 5.7 Graphical representation of the Mean $\pm$ SEM of Bcl-2 protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities. 115

Graph 5.8 Graphical representation of Bax/Bcl-2 index values in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained by dividing the values of Bax protein fluorescent intensities by Bcl-2 protein fluorescent intensities. 117

Graph 5.9 Graphical representation of the Bax/Bcl-2 index values in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained by dividing the values of Bax protein fluorescent intensities by Bcl-2 protein fluorescent intensities. 117

Graph 5.10 Graphical representation of Bax gene expression as compared to day 5.5 in the control pregnant animals, the calibrator sample. 119

Graph 5.11 Graphical representation of Bcl-2 gene expression as compared to day 5.5 in the control pregnant animals, the calibrator sample. 119

CHAPTER 6: THE EFFECT OF RU486 ON ANGIOGENESIS DURING EARLY PREGNANCY IN THE RAT UTERUS

Graph 6.1 Graphical representation of the Mean $\pm$ SEM of VEGF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C), the glandular stroma (D), the blood vessels (E) and the stroma surrounding the blood vessels (F) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities. 145

Graph 6.2 Graphical representation of the Mean $\pm$ SEM of bFGF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C), the glandular stroma (D), the blood vessels (E) and the stroma surrounding the blood vessels (F) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities. 147

Graph 6.3 Graphical representation of the Mean $\pm$ SEM of VEGF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C), the glandular stroma (D), the blood vessels (E) and the stroma surrounding the blood vessels (F) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5

pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	151
Graph 6.4 Graphical representation of the Mean $\pm$ SEM of bFGF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C), the glandular stroma (D), the blood vessels (E) and the stroma surrounding the blood vessels (F) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	153
Graph 6.5 Graphical representation of the Mean $\pm$ SEM of VEGF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C), the glandular stroma (D), the blood vessels (E) and the stroma surrounding the blood vessels (F) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	155
Graph 6.6 Graphical representation of the Mean $\pm$ SEM of bFGF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C), the glandular stroma (D), the blood vessels (E) and the stroma surrounding the blood vessels (F) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	157
Graph 6.7 Graphical representation of the Mean $\pm$ SEM of PDGF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C), the glandular stroma (D), the blood vessels (E) and the stroma surrounding the blood vessels (F) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	167
Graph 6.8 Graphical representation of the Mean $\pm$ SEM of PDGF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C), the glandular stroma (D), the blood vessels (E) and the stroma surrounding the blood vessels (F) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	171
Graph 6.9 Graphical representation of the Mean $\pm$ SEM of PDGF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C), the glandular stroma (D), the blood vessels (E) and the stroma surrounding the blood vessels (F) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	173
Graph 6.10 Graphical representation of VEGF gene expression as compared to day 5.5 in the control pregnant animals, the calibrator sample.	178
Graph 6.11 Graphical representation of bFGF gene expression as compared to day 5.5 in the control pregnant animals, the calibrator sample.	178
Graph 6.12 Graphical representation of PDGF gene expression as compared to day 5.5 in the control pregnant animals, the calibrator sample.	181

CHAPTER 7: THE EFFECTS OF RU486 ON SELECTED ENDOMETRIAL BIOMARKERS DURING EARLY PREGNANCY IN THE RAT UTERUS

Graph 7.1 Graphical representation of the Mean $\pm$ SEM of LIF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the

glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	213
Graph 7.2 Graphical representation of the Mean $\pm$ SEM of Muc-1 protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	215
Graph 7.3 Graphical representation of the Mean $\pm$ SEM of Calcitonin protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	215
Graph 7.4 Graphical representation of the Mean $\pm$ SEM of LIF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	223
Graph 7.5 Graphical representation of the Mean $\pm$ SEM of Muc-1 protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	223
Graph 7.6 Graphical representation of the Mean $\pm$ SEM of Calcitonin protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	225
Graph 7.7 Graphical representation of the Mean $\pm$ SEM of LIF protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	225
Graph 7.8 Graphical representation of the Mean $\pm$ SEM of Muc-1 protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	227
Graph 7.9 Graphical representation of the Mean $\pm$ SEM of Calcitonin protein expression in the luminal epithelium (A), the subepithelial stroma (B), the glandular epithelium (C) and the glandular stroma (D) of the implantation (IS) and non-implantation (NIS) sites in day 4.5, day 5.5 and day 6.5 pregnant rat uteri treated with vehicle (UT) or RU486 (T) at day 3.0 of pregnancy, as obtained from image analysis of fluorescent intensities.	227
Graph 7.10 Graphical representation of LIF gene expression as compared to day 5.5 in the control pregnant animals, the calibrator sample.	236
Graph 7.11 Graphical representation of Muc-1 gene expression as compared to day 5.5 in the control pregnant animals, the calibrator sample.	236
Graph 7.12 Graphical representation of Calcitonin gene expression as compared to day 5.5 in the control pregnant animals, the calibrator sample.	237

LIST OF TABLES

Table	Page
CHAPTER 2: MATERIALS AND METHODS	
Table 2.1 The micrographs of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy of the control animals and animals treated with RU486 at day 3 of pregnancy were analysed with regards to six uterine epithelial cell characteristics. The scoring system for each characteristic is described below.	13
Table 2.2 The Ensembl Identification numbers for the angiogenic pathway-related and Apoptotic pathway-related gene transcripts and the Ensembl Identification number of the gene the transcript is a product of.	19
Table 2.3 Primers used and product size.	20
Table 2.4 RT Reaction mix for the synthesis of cDNA from total RNA.	21
Table 2.5 Thermal cycling parameters for reverse transcription.	22
Table 2.6 TaqMan gene expression PCR reaction mix.	25
Table 2.7 Thermal cycling parameters for TaqMan real-time PCR.	25
Table 2.8 SYBR Green PCR reaction mix.	28
Table 2.9 Thermal cycling parameters for SYBR Green real-time PCR.	27
Table 2.10 IF tissue section preparation for the endometrial biomarkers, and the apoptotic and angiogenic pathway-related proteins.	29
CHAPTER 3: THE EFFECT OF RU486 ON THE WINDOW OF RECEPTIVITY	
Table 3.1 Results table of the scanning electron microscopy analysis. The six luminal epithelial characteristics are as described in section 2.3.1.3, in both the implantation and non-implantation sites of the control pregnant (UT) and the RU486-treated animals (T) at days 4.5, 5.5 and 6.5 of pregnancy.	39
Table 3.2 Overview of the results obtained from the transmission electron microscopy and Toluidine Blue light microscopy morphological analysis of the criteria set out in section 2.3.2.3 for the implantation (IS) and non-implantation (NIS) sites of the control pregnant (UT) and RU486-treated (T) animals. The characteristics of the endometrium are listed in order from the luminal surface through to the stromal compartments and the glandular epithelium.	41
Table 3.2 cont. Overview of the results obtained from the transmission electron microscopy and Toluidine Blue light microscopy morphological analysis of the criteria set out in section 2.3.2.3 for the implantation (IS) and non-implantation (NIS) sites of the control pregnant (UT) and RU486-treated (T) animals. The characteristics of the endometrium are listed in order from the luminal surface through to the stromal compartments and the glandular epithelium.	43
CHAPTER 4: THE EFFECT OF RU486 ON PROGESTERONE RECEPTOR LOCALISATION AND EXPRESSION IN THE RAT UTERUS DURING EARLY PREGNANCY	
Table 4.1 One-way ANOVA and Tukey Kramer <i>post hoc</i> analysis of PR protein expression in the luminal epithelium, the subepithelial stroma, the glandular epithelium and the glandular stroma of the implantation (IS) and non-implantation (NIS) sites between days 4.5, 5.5 and 6.5 in the control pregnant (UT) and RU486-treated (T) animals showing groups that are significantly different ($p \leq 0.05$). Groups not connected by the same letter are significantly	

different. 73

Table 4.2 RQ analysis of PR gene expression in the implantation (IS) and non-implantation (NIS) sites at day 5.5 and 6.5 of pregnancy in the control pregnant (UT) and RU486-treated (T) animals. A fold change of 2 or more denotes a significant difference in gene expression. 83

CHAPTER 5: THE ROLE OF RU486 IN INDUCING APOPTOSIS DURING EARLY PREGNANCY; ASSESSMENT USING THE BAX/BCL-2 INDEX

Table 5.1 One-way ANOVA and Tukey Kramer *post hoc* analysis of Bax protein expression in the luminal epithelium, the subepithelial stroma, the glandular epithelium and the glandular stroma of the implantation (IS) and non-implantation (NIS) sites between days 4.5, 5.5 and 6.5 in the control pregnant (UT) and RU486-treated (T) animals showing groups that are significantly different ($p \leq 0.05$). Groups not connected by the same letter are significantly different. 100

Table 5.2 One-way ANOVA and Tukey Kramer *post hoc* analysis of Bcl-2 protein expression in the luminal epithelium, the subepithelial stroma, the glandular epithelium and the glandular stroma of the implantation (IS) and non-implantation (NIS) sites between days 4.5, 5.5 and 6.5 in the control pregnant (UT) and RU486-treated (T) animals showing groups that were significantly different ($p \leq 0.05$). Groups not connected by the same letter are significantly different. 102

Table 5.3 Bax and Bcl-2 protein levels were evaluated as mean fluorescent intensities using the image analysis software, analySIS Life Science Research program FIVE – Digital imaging Solutions (Olympus Soft Imaging Solutions). In this table, the results are expressed as an index (Bax/Bcl-2), obtained by dividing the Bax mean fluorescent intensity by the Bcl-2 mean fluorescent intensity. This was done for the endometrial compartments; the luminal epithelium, subepithelial stroma, glandular epithelium and the glandular stroma of both the implantation (IS) and non-implantation (NIS) sites of the control pregnant (UT) and RU486-treated (T) animals at days 4.5, 5.5 and 6.5 of pregnancy. 108

Table 5.4 RQ analysis of Bax and Bcl-2 gene expression in the implantation (IS) and non-implantation (NIS) sites at day 5.5 and 6.5 of pregnancy in the control pregnant (UT) and RU486-treated (T) animals. A fold change of 2 or more denotes a significant difference in gene expression. 120

CHAPTER 6: THE EFFECT OF RU486 ON ANGIOGENESIS DURING EARLY PREGNANCY IN THE RAT UTERUS

Table 6.1 One-way ANOVA and Tukey Kramer *post hoc* analysis of VEGF protein expression in the luminal epithelium, the subepithelial stroma, the glandular epithelium, the glandular stroma, the blood vessels and the stroma surrounding the blood vessels of the implantation (IS) and non-implantation (NIS) sites between days 4.5, 5.5 and 6.5 in the control pregnant (UT) and RU486-treated (T) animals showing groups that are significantly different ($p \leq 0.05$). Groups not connected by the same letter are significantly different. 140

Table 6.2 One-way ANOVA and Tukey Kramer *post hoc* analysis of bFGF protein expression in the luminal epithelium, the subepithelial stroma, the glandular epithelium, the glandular stroma, the blood vessels and the stroma surrounding the blood vessels of the implantation (IS) and non-implantation (NIS) sites between days 4.5, 5.5 and 6.5 in the control pregnant (UT) and RU486-treated (T) animals showing groups that are significantly different ($p \leq 0.05$). Groups not connected by the same letter are significantly different. 142

Table 6.3 One-way ANOVA and Tukey Kramer *post hoc* analysis of PDGF protein

expression in the luminal epithelium, the subepithelial stroma, the glandular epithelium, the glandular stroma, the blood vessels and the stroma surrounding the blood vessels of the implantation (IS) and non-implantation (NIS) sites between days 4.5, 5.5 and 6.5 in the control pregnant (UT) and RU486-treated (T) animals showing groups that are significantly different ($p \leq 0.05$). Groups not connected by the same letter are significantly different. 164

Table 6.4 RQ analysis of VEGF and bFGF gene expression in the implantation (IS) and non-implantation (NIS) sites at day 5.5 and 6.5 of pregnancy in the control pregnant (UT) and RU486-treated (T) animals. A fold change of 2 or more represents a significant difference in gene expression. 177

Table 6.5 RQ analysis of PDGF gene expression in the implantation (IS) and non-implantation (NIS) sites at day 5.5 and 6.5 of pregnancy in the control pregnant (UT) and RU486-treated animals. A fold change of 2 or more represents a significant difference in gene expression. 181

CHAPTER 7: THE EFFECTS OF RU486 ON SELECTED ENDOMETRIAL BIOMARKERS DURING EARLY PREGNANCY IN THE RAT UTERUS

Table 7.1 One-way ANOVA and Tukey Kramer *post hoc* analysis of LIF protein expression in the luminal epithelium, the subepithelial stroma, the glandular epithelium and the glandular stroma of the implantation (IS) and non-implantation (NIS) sites between days 4.5, 5.5 and 6.5 in the control pregnant (UT) and RU486-treated (T) animals showing groups that are significantly different ($p \leq 0.05$). Groups not connected by the same letter are significantly different. 210

Table 7.2 One-way ANOVA and Tukey Kramer *post hoc* analysis of Muc-1 protein expression in the luminal epithelium, the subepithelial stroma, the glandular epithelium and the glandular stroma of the implantation (IS) and non-implantation (NIS) sites between days 4.5, 5.5 and 6.5 in the control pregnant (UT) and RU486-treated (T) animals showing groups that were significantly different ($p \leq 0.05$). Groups not connected by the same letter are significantly different. 212

Table 7.3 One-way ANOVA and Tukey Kramer *post hoc* analysis of Calcitonin protein expression in the luminal epithelium, the subepithelial stroma, the glandular epithelium and the glandular stroma of the implantation (IS) and non-implantation (NIS) sites between days 4.5, 5.5 and 6.5 in the control pregnant (UT) and RU486-treated (T) animals showing groups that are significantly different ($p \leq 0.05$). Groups not connected by the same letter are significantly different. 214

Table 7.4 RQ analysis of LIF, Muc-1 and Calcitonin gene expression in the implantation (IS) and non-implantation (NIS) sites at day 5.5 and 6.5 of pregnancy in the control pregnant (UT) and RU486-treated (T) animals. A fold change of 2 or more represents a significant difference in gene expression. 235

APPENDIX C: STATISTICAL ANALYSIS FOR IMMUNOFLUORESCENCE

Table 9.1 Mean and standard error of the mean values of PR protein expression in the regions of interest of the control pregnant and RU486-treated animals at day 4.5, 5.5 and 6.5 of pregnancy. 292

Table 9.2 Tests for homogeneity of the data (equality of variance) for PR protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p = 0.05$) 292

Table 9.3 Welch ANOVA test for significant differences between the mean PR protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the control pregnant and RU486-treated animals ($p=0.05$)	293
Table 9.4 Mean and standard error of the mean values of Bax protein expression in the regions of interest of the control pregnant and RU486-treated animals at day 4.5, 5.5 and 6.5 of pregnancy.	294
Table 9.5 Tests for homogeneity of the data (equality of variance) for Bax protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p=0.05$)	295
Table 9.6 Welch ANOVA test for significant differences between the mean Bax protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the RU486-treated and the untreated animals ($p=0.05$)	295
Table 9.7 Mean and standard error of the mean values of Bcl-2 protein expression in the regions of interest of the control pregnant and RU486-treated animals at day 4.5, 5.5 and 6.5 of pregnancy.	297
Table 9.8 Tests for homogeneity of the data (equality of variance) for Bcl-2 protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p=0.05$)	297
Table 9.9 Welch ANOVA test for significant differences between the mean Bcl-2 protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the control pregnant and RU486-treated animals ($p=0.05$)	298
Table 9.10 Mean and standard error of the mean values of VEGF protein expression in the regions of interest of the control pregnant and RU486-treated animals at day 4.5, 5.5 and 6.5 of pregnancy.	300
Table 9.11 Tests for homogeneity of the data (equality of variance) for VEGF protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p=0.05$)	301
Table 9.12 Welch ANOVA test for significant differences between the mean VEGF protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the RU486-treated and the untreated animals ($p=0.05$)	301
Table 9.13 Mean and standard error of the mean values of bFGF protein expression in the regions of interest of the control pregnant and RU486-treated animals at day 4.5, 5.5 and 6.5 of pregnancy.	304
Table 9.14 Tests for homogeneity of the data (equality of variance) for bFGF protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p=0.05$)	305
Table 9.15 Welch ANOVA test for significant differences between the mean bFGF protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the control pregnant and RU486-treated animals ($p=0.05$)	305
Table 9.16 Mean and standard error of the mean values of PDGF protein expression in the regions of interest of the control pregnant and RU486-treated animals at day 4.5, 5.5 and 6.5 of pregnancy.	308

Table 9.17 Tests for homogeneity of the data (equality of variance) for PDGF protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p=0.05$)	309
Table 9.18 Welch ANOVA test for significant differences between the mean PDGF protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the control pregnant and RU486-treated animals ($p=0.05$)	309
Table 9.19 Mean and standard error of the mean values of LIF protein expression in the regions of interest of the control pregnant and RU486-treated animals at day 4.5, 5.5 and 6.5 of pregnancy.	312
Table 9.20 Tests for homogeneity of the data (equality of variance) for LIF protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p=0.05$)	312
Table 9.21 Welch ANOVA test for significant differences between the mean LIF protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the control pregnant and RU486-treated animals ($p=0.05$)	313
Table 9.22 Mean and standard error of the mean values of Muc-1 protein expression in the regions of interest of the control pregnant and RU486-treated animals at day 4.5, 5.5 and 6.5 of pregnancy.	314
Table 9.23 Tests for homogeneity of the data (equality of variance) for Muc-1 protein expression in the regions of interest in the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p=0.05$)	315
Table 9.24 Welch ANOVA test for significant differences between the mean Muc-1 protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the control pregnant and RU486-treated animals ($p=0.05$)	315
Table 9.25 Mean and standard error of the mean values of Calcitonin protein expression in the regions of interest of the control pregnant and RU486-treated animals at day 4.5, 5.5 and 6.5 of pregnancy.	317
Table 9.26 Tests for homogeneity of the data (equality of variance) for Calcitonin protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p=0.05$)	317
Table 9.27 Tests for homogeneity of the data (equality of variance) for Calcitonin protein expression in the regions of interest of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in control pregnant and RU486-treated animals, using the O'Brien's, Brown-Forsythe's, Levene's and Bartlett's tests ($p=0.05$)	318
Table 9.28 Welch ANOVA test for significant differences between the mean Calcitonin protein expression in the glandular stroma of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the RU486-treated and the untreated animals ($p=0.05$)	318
Table 9.29 One-way analysis of variance test for significant differences between the mean Calcitonin protein expression in the glandular stroma of the implantation and non-implantation sites at day 4.5, 5.5 and 6.5 of pregnancy in the RU486-treated and the control pregnant animals ($p=0.05$)	318

NOMENCLATURE

α	alpha
β	beta
ΔCT	change in threshold cycle
1° Ab	primary antibody
2° AB	secondary antibody
°C	degrees Celsius
%	percent
(-/-)	wild type
A_{230}	absorbance at 230nm
A_{260}	absorbance at 260nm
A_{280}	absorbance at 280nm
A	adenine
Ab	antibody
ACE	Associated Chemical Enterprises
ANOVA	one-way analysis of variance
AR	androgen receptor
bFGF	basic fibroblast growth factor
bps	base pairs
BSA	bovine serum albumin
BV	blood vessels
C	cytosine
cAMP	cyclic adenosine monophosphate
cDNA	complementary deoxyribonucleic acid
CO ₂	carbon dioxide
CT	threshold cycle
DBD	DNA binding domain
DF	degrees of freedom
dH ₂ O	distilled water
DNA	deoxyribonucleic acid
E	endogenous control
EC	emergency contraception
ECM	extracellular matrix
EDTA	ethylenediamine tetraacetate
EM	electron microscopy
ER	oestrogen receptor
ER α	oestrogen receptor alpha

ER β	oestrogen receptor beta
ERKO	oestrogen receptor knockout
FasL	Fas ligand
FGF	fibroblast growth factor
FGFR	fibroblast growth factor receptor
Flt-1	c-fms-like tyrosine kinase
Flk-1	kinase domain insert-containing receptor
FN	fibronectin
FRET	fluorescent resonance energy transfer
G	guanine
gp130	glycoprotein 130
GR	glucocorticoid receptor
HeLa	uterine cervical adenocarcinoma cell line
HP	Hewlett Packard
hsp90	90kDa heat shock protein
IF	immunofluorescence
IFN- γ	interferon γ
IFP	intermediate filament protein
IgG	immunoglobulin-G
IP	intraperitoneal
IS	implantation sites
kDa	kilo Daltons
KDR	kinase domain insert-containing receptor
kV	kilo volts
LBD	ligand binding domain
LIF	leukaemia inhibitory factor
LIFR	leukaemia inhibitory factor receptor
mA	milliamps
mg	milligram
MGB	minor groove binder
ml	millilitre
mm	millimetre
mM	millimolar
mRNA	messenger ribonucleic acid
Muc-1	mucin 1
n	sample size (number of observations)
NaOH	sodium hydroxide

NCBI	National Centre for Biotechnology Information
NcoR	nuclear receptor co-repressor
NEM	<i>N</i> -ethylmaleimide
NFQ	nonfluorescent quencher
N.H.	Null Hypothesis
NIS	non-implantation sites
NK	natural killer cells
nM	nanomolar
nm	nanometre
NRP-1	neuropilin-1
NTC	no template control
ODN	oligodeoxynucleotide
OPN	osteopontin
P	progesterone
p<0.05	significantly different at the 5% level of significance
p>0.05	not significantly different at the 5% level of significance
PA	progesterone receptor antagonist
PBS	phosphate buffered saline
PCR	polymerase chain reaction
PDGF	platelet-derived growth factor
PDGFR	platelet-derived growth factor receptor
pH	potential hydrogen
PMT	plasma membrane transformation
PO ₄	phosphate buffer (pH 7.2)
PPI	pixels per inch
PR	progesterone receptor
PR-A	progesterone receptor isoform A
PR-B	progesterone receptor isoform B
PRAKO	progesterone receptor-A knockout
PRBKO	progesterone receptor-B knockout
PRE	progesterone response element
PRM	progesterone receptor modulator
PRKO	progesterone receptor knockout
RNA	ribonucleic acid
ROI	region of interest
RQ	relative quantification
rRNA	ribosomal ribonucleic acid

RT	room temperature
RT	reverse transcriptase/transcription
-RT	minus reverse transcriptase control
RT-qPCR	quantitative reverse transcription polymerase chain reaction
SEM	scanning electron microscopy
SEM	standard error of the mean
SMRT	silencing mediator of retinoic acid and thyroid hormone receptor
SRC	steroid receptor co-activator
T	target
T	thymine
T	treated (RU486-treated animals)
TBE	tris borate EDTA
TEM	transmission electron microscopy
TNF- α	tumour necrosis factor α
TNFR	tumour necrosis factor receptor
μ g	microgram
UGKO	uterine gland knockout
μ l	microlitre
μ m	micrometer
USA	United States of America
UT	untreated (control pregnant animals)
UTMP	uterine milk protein
VEGF	vascular endothelial growth factor
VEGFR	vascular endothelial growth factor receptor
VNTR	variable number of tandem repeats
VPF	vascular permeability factor
v/v	volume to volume
W	watt
WHO	World Health Organisation
w/v	weight to volume